ArticleCancer research communications2026
Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutropenia is an adverse event of systemic chemotherapy with various complications that affect patient management, quality of life, and could be fatal. The study was conducted to evaluate chemotherapy-induced neutropenia (CIN) in a Palestinian cohort of patients with solid malignancies. This article examines patient characteristics, risk factors for neutropenia severity, and neutropenia management patterns. The study included a total of 171 adult patients diagnosed with solid malignancies who were on their first chemotherapy regimens with no history of neutropenia. Data were collected retrospectively from patients' electronic medical records. Only patients who developed neutropenia during treatment were included in this study, and patients were classified into three groups of severity based on the absolute neutrophil count (ANC). Colon cancer and lung cancer were the most reported. Epirubicin, paclitaxel, cyclophosphamide, and doxorubicin were significantly associated with neutropenia severity, in addition to the number of chemotherapy cycles, stage at diagnosis, and certain comorbidities. Of the total patients, 32.5% reported substance use which was also significantly associated with severity. The majority of patients received primary granulocyte colony-stimulating factor (GCSF) prophylaxis. Sixty-nine percent of patients presented with febrile neutropenia. Hospitalization, antibiotics, antipyretics, and GCSF were utilized for management in most patients. Neutropenia severity was associated with the chemotherapy agents used, whereas the type of solid malignancy was not. Substance use represented a high burden among our cohort, and its association with severity could be further studied. Primary GCSF prophylaxis is critical, with patients not receiving it developing profound neutropenia (ANC <0.1 × 109) at higher rates. SIGNIFICANCE: CIN causes high utilization of medical resources and disrupts treatment schedules. Factors possibly associated with severity include stage at diagnosis, number of chemotherapy cycles, select agents, and comorbidities. GCSF prophylaxis possibly decreases profound neutropenia rates. Palestinian patients with cancer have a high burden of substance use, possibly reflecting unmet needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.